This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. 3 The 5-year mortality rate after nontraumatic major amputations of the lower extremity is estimated to range from 52% to 80%. If left untreated, PAD can lead to gangrene and limb amputation. Twelve to 20 percent of Americans over 60 years old have PAD 2, which increases risk of coronary artery disease, heart attack and stroke, and can impair the ability to walk. Worldwide, over 200 million people have PAD 1, a serious and underdiagnosed circulatory condition caused by build-up of arterial plaque, most commonly in the legs. With the clot entrained, the system is withdrawn into a minimum 7 Fr guide sheath through which the clot is withdrawn and removed from the body.įor more information on the Pounce Thrombectomy System, visit About Peripheral Artery Disease (PAD) The baskets capture the clot and are retracted into a nitinol collection funnel. The basket wire is delivered distal to the location of the thrombus, deploying two nitinol self-expanding baskets. The device is comprised of three components: a 5 Fr delivery catheter, a basket wire, and a funnel catheter. The Pounce Thrombectomy System is intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. “The Pounce Thrombectomy System represents a significant advancement in the treatment of patients with complex peripheral artery disease (PAD) while also focusing on ease of use and efficiency for the physicians treating these patients.” “I am delighted to present this FIH data,” said Ansel. The Pounce Thrombectomy System is an intuitive ‘grab and go’, non-aspiration, mechanical thrombectomy solution that empowers physicians to strike quickly to capture and remove clot from the peripheral vasculature without requiring external capital equipment for operation. Ansel, the inventor of the Pounce Thrombectomy System and a consultant for Surmodics, will review results from the first 20 thrombectomy procedures performed with the Pounce device across six U.S. 2020 and the first patient use of the device occurred in June 2021. The Pounce Thrombectomy System received clearance from the U.S. VENUE: Hilton London Metropole, Richmond Room TITLE: First In Man: A truly percutaneous nonsuction-based thromboembolectomy catheter approach ![]() (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Gary Ansel, MD, will present First-In-Human (FIH) data on the company’s Pounce™ Thrombectomy System on Tuesday, April 26, at the Charing Cross International Symposium in London. EDEN PRAIRIE, Minn.-( BUSINESS WIRE)-Surmodics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |